Trial Profile
Dose Adjustment Trial of SK-1403 in Hemodialysis Patients With Secondary Hyperparathyroidism
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Upacicalcet (Primary)
- Indications Secondary hyperparathyroidism
- Focus Therapeutic Use
- Sponsors Sanwa Kagaku Kenkyusho
- 14 Mar 2019 Status changed from active, no longer recruiting to completed.
- 09 Jul 2018 Planned End Date changed from 1 Nov 2018 to 1 Mar 2019.
- 09 Jul 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Sep 2018.